Literature DB >> 12552010

High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host.

Alberto López-Bueno1, Mauricio G Mateu, José M Almendral.   

Abstract

The degree of genetic heterogeneity of DNA virus populations in nature and its consequences for disease control are virtually unknown. The parvovirus minute virus of mice (MVMi) was used here to investigate (i) the frequency of antibody-escape mutants in populations of a DNA virus and (ii) the ability of a DNA virus to evade in the long-term a passive monoclonal antibody (MAb) therapy in an immunodeficient natural host. Independent clonal populations of MVMi harbored a high proportion of mutants resistant to neutralizing MAb (mutant frequency = [2.8 +/- 0.5] x 10(-5)) that rapidly evolved under antibody pressure in culture to become mixtures dominated by genotypically diverse escape mutants. Immunodeficient mice naturally infected with clonal populations of MVMi and subsequently treated by intravenous injections of MAb were initially protected from the characteristic viral induced lethal leukopenia. However, some treated animals developed a delayed severe leukopenic syndrome associated with the emergence of genetically heterogeneous populations of MAb-resistant mutants in the MVMi main target organs. The 11 plaque-purified viruses analyzed from an antibody-resistant population obtained from one animal corresponded to four different mutant genotypes, although their consensus sequence remained wild type. All cloned escape mutants harbored single radical amino acid changes within a stretch of seven residues in a surface-exposed loop at the threefold axes of the capsid. This antigenic site, which can tolerate radical changes preserving MVMi pathogenic potential, may thereby allow the virus to evade the immune control. These findings indicate a high genetic heterogeneity and rapid adaptation of populations of a mammal DNA virus in vivo and provide a genetic basis for the failure of passive immunotherapy in the natural host.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552010      PMCID: PMC141124          DOI: 10.1128/jvi.77.4.2701-2708.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.

Authors:  Z Yan; Y Zhang; D Duan; J F Engelhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

Review 3.  RNA virus mutations and fitness for survival.

Authors:  E Domingo; J J Holland
Journal:  Annu Rev Microbiol       Date:  1997       Impact factor: 15.500

Review 4.  Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants.

Authors:  E Domingo; L Menéndez-Arias; M E Quiñones-Mateu; A Holguín; M Gutiérrez-Rivas; M A Martínez; J Quer; I S Novella; J J Holland
Journal:  Prog Drug Res       Date:  1997

5.  Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity.

Authors:  Y T Hwang; B Y Liu; D M Coen; C B Hwang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

Authors:  M C Gauduin; P W Parren; R Weir; C F Barbas; D R Burton; R A Koup
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

7.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

8.  Multiple amino acids in the capsid structure of canine parvovirus coordinately determine the canine host range and specific antigenic and hemagglutination properties.

Authors:  S F Chang; J Y Sgro; C R Parrish
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Human parvovirus B19 as a causative agent for rheumatoid arthritis.

Authors:  Y Takahashi; C Murai; S Shibata; Y Munakata; T Ishii; K Ishii; T Saitoh; T Sawai; K Sugamura; T Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Functional implications of the structure of the murine parvovirus, minute virus of mice.

Authors:  M Agbandje-McKenna; A L Llamas-Saiz; F Wang; P Tattersall; M G Rossmann
Journal:  Structure       Date:  1998-11-15       Impact factor: 5.006

View more
  29 in total

1.  Role of interfacial amino acid residues in assembly, stability, and conformation of a spherical virus capsid.

Authors:  Juan Reguera; Aura Carreira; Laura Riolobos; José María Almendral; Mauricio G Mateu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

2.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

3.  High-frequency reversion of geminivirus replication protein mutants during infection.

Authors:  Gerardo Arguello-Astorga; J Trinidad Ascencio-Ibáñez; Mary Beth Dallas; Beverly M Orozco; Linda Hanley-Bowdoin
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

4.  Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome.

Authors:  Bernhard Mani; Claudia Baltzer; Noelia Valle; José M Almendral; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Host-selected amino acid changes at the sialic acid binding pocket of the parvovirus capsid modulate cell binding affinity and determine virulence.

Authors:  Alberto López-Bueno; Mari-Paz Rubio; Nathan Bryant; Robert McKenna; Mavis Agbandje-McKenna; José M Almendral
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Mixed genotype transmission bodies and virions contribute to the maintenance of diversity in an insect virus.

Authors:  Gabriel Clavijo; Trevor Williams; Delia Muñoz; Primitivo Caballero; Miguel López-Ferber
Journal:  Proc Biol Sci       Date:  2009-11-25       Impact factor: 5.349

7.  Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.

Authors:  Päivi Norja; Kati Hokynar; Leena-Maija Aaltonen; Renwei Chen; Annamari Ranki; Esa K Partio; Olli Kiviluoto; Irja Davidkin; Tomi Leivo; Anna Maria Eis-Hübinger; Beate Schneider; Hans-Peter Fischer; René Tolba; Olli Vapalahti; Antti Vaheri; Maria Söderlund-Venermo; Klaus Hedman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

8.  Virulent variants emerging in mice infected with the apathogenic prototype strain of the parvovirus minute virus of mice exhibit a capsid with low avidity for a primary receptor.

Authors:  Mari-Paz Rubio; Alberto López-Bueno; José M Almendral
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  A supraphysiological nuclear export signal is required for parvovirus nuclear export.

Authors:  Dieuwke Engelsma; Noelia Valle; Alexander Fish; Nathalie Salomé; José M Almendral; Maarten Fornerod
Journal:  Mol Biol Cell       Date:  2008-04-02       Impact factor: 4.138

10.  Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints.

Authors:  L H Vandenberghe; E Breous; H-J Nam; G Gao; R Xiao; A Sandhu; J Johnston; Z Debyser; M Agbandje-McKenna; J M Wilson
Journal:  Gene Ther       Date:  2009-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.